Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D Smith

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
JMIR Formative Research|December 9, 2024
Evaluation of RMES, an Automated Software Tool Utilizing AI, for Literature Screening with Reference to Published Systematic Reviews as Case-Studies: Development and Usability StudyAyaka Sugiura, Satoshi Saegusa, Yingzi Jin, et al.
Data in Brief|May 26, 2023
Data on eye movements of glaucoma patients with asymmetrical visual field loss during free viewingPeter Reddingius, Daniel S Asfaw, Vera M Mönter, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodologyBrian Eastman, Chixu Chen, Nicholas D Smith, et al.
Molecular Cancer Therapeutics|June 21, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signalingRentian Feng, Huihui Ma, Christian A Hassig, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonistSteve F Poon, Brian W Eastman, Deborah F Chapman, et al.
Plos One|March 20, 2010
Exploring eye movements in patients with glaucoma when viewing a driving sceneDavid P Crabb, Nicholas D Smith, Franziska G Rauscher, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Novel approach to pro-drugs of lactones: water soluble imidate and ortho-ester derivatives of a furanone-based COX-2 selective inhibitorSteve F Poon, Nicholas Stock, Joseph E Payne, et al.
Journal of Hepatology|February 13, 2021
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitisStephen A Harrison, Mustafa R Bashir, Kyoung-Jin Lee, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2005
Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemiaNicholas D Smith, Thomas S Reger, Joseph Payne, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonistDehua Huang, Steve F Poon, Deborah F Chapman, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
JMIR Formative Research|December 9, 2024
Evaluation of RMES, an Automated Software Tool Utilizing AI, for Literature Screening with Reference to Published Systematic Reviews as Case-Studies: Development and Usability StudyAyaka Sugiura, Satoshi Saegusa, Yingzi Jin, et al.
Data in Brief|May 26, 2023
Data on eye movements of glaucoma patients with asymmetrical visual field loss during free viewingPeter Reddingius, Daniel S Asfaw, Vera M Mönter, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodologyBrian Eastman, Chixu Chen, Nicholas D Smith, et al.
Molecular Cancer Therapeutics|June 21, 2008
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signalingRentian Feng, Huihui Ma, Christian A Hassig, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonistSteve F Poon, Brian W Eastman, Deborah F Chapman, et al.
Plos One|March 20, 2010
Exploring eye movements in patients with glaucoma when viewing a driving sceneDavid P Crabb, Nicholas D Smith, Franziska G Rauscher, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Novel approach to pro-drugs of lactones: water soluble imidate and ortho-ester derivatives of a furanone-based COX-2 selective inhibitorSteve F Poon, Nicholas Stock, Joseph E Payne, et al.
Journal of Hepatology|February 13, 2021
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitisStephen A Harrison, Mustafa R Bashir, Kyoung-Jin Lee, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2005
Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemiaNicholas D Smith, Thomas S Reger, Joseph Payne, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonistDehua Huang, Steve F Poon, Deborah F Chapman, et al.
Pageof 7